(Reuters) – The U.S. Food and Drug Administration has rejected Chiasma Inc’s experimental drug to treat adults with a type of growth disorder, the company said on Friday. Chiasma was evaluating the drug, Mycapssa, in patients with acromegaly, a growth disorder that can result in serious illness and premature death. The Food and Drug Administration issued a complete response letter for Mycapssa indicating that the review cycle for the application was complete and that the therapy was not ready for approval in its present form, Chiasma said in a statement.

See original here:
FDA rejects Chiasma’s drug to treat growth disorder